PDF 155kWORD 46k

pursuant to Rule 133 of the Rules of Procedure

on vaccines containing aluminium salts

Mireille D'Ornano

Motion for a European Parliament resolution on vaccines containing aluminium salts  

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to Rule 133 of its Rules of Procedure,

A.  whereas several reliable scientific studies have pointed to a probable causal link between the presence of aluminium salts in vaccines and a rise in the number of cases of autism in the countries where they are used the most, and whereas one study in particular, carried out by the University of British Columbia (Canada, 2011), has revealed that using these vaccines increases the risk of neurological disorders;

B.  whereas, on 27 July 2012, the World Health Organisation issued a positive benefit-risk assessment of the link between the risk of autism and the use of aluminium adjuvants, but that other health risks, particularly those discussed in recital A, have yet to be taken into account;

1.  Encourages the Commission to conduct research through the European Centre For Disease Prevention and Control into the risks associated with vaccines containing aluminium adjuvants.

Legal notice - Privacy policy